Finance

Lists
000739:SHE
Apeloa Pharmaceutical Co Ltd
CNÂ¥24.82
+5.71%
(+1.34) 1D
Sep 21, 3:04:54 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000739...
Open
CNÂ¥23.50
High
CNÂ¥24.88
Low
CNÂ¥23.48
Mkt. cap
27.20B
Avg. vol.
23.74M
Volume
20.41M
P/E ratio
33.68
52-wk high
CNÂ¥24.88
52-wk low
CNÂ¥14.89
EPS
CNÂ¥0.74
Shares outstanding
1.16B
No. of employees
7K
Open
CNÂ¥23.50
High
CNÂ¥24.88
Low
CNÂ¥23.48
Mkt. cap
27.20B
Avg. vol.
23.74M
Volume
20.41M
P/E ratio
33.68
52-wk high
CNÂ¥24.88
52-wk low
CNÂ¥14.89
EPS
CNÂ¥0.74
Shares outstanding
1.16B
No. of employees
7K
Profile
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas. Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development. Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
About Apeloa Pharmaceutical Co Ltd
CEO-
Employees6.79K
Founded1989
Headquarters-
SectorPharmaceutical industry
Websiteapeloa.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.32B
2.02B
2.45B
2.38B
Cost of goods sold
1.75B
1.48B
1.73B
1.69B
Cost of revenue
1.75B
1.48B
1.73B
1.69B
Research and development expenses
140.81M
146.16M
134.93M
143.88M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
231.94M
275.50M
219.12M
203.71M
Operating expense
330.71M
483.17M
380.47M
371.82M
Total operating expenses
2.08B
1.96B
2.11B
2.06B
Operating income
239.75M
60.19M
336.71M
311.76M
Other non operating income
-7.84M
7.46M
-33.21M
31.72M
EBT including unusual items
180.55M
227.06M
297.81M
323.80M
EBT excluding unusual items
242.07M
80.73M
306.22M
288.49M
Income tax expense
43.43M
36.57M
48.54M
50.52M
Effective tax rate
24.06%
16.10%
16.30%
15.60%
Other operating expenses
-29.24M
53.54M
13.18M
11.46M
Net income
137.22M
190.41M
249.02M
273.35M
Net profit margin
5.92%
9.43%
10.17%
11.51%
Earnings per share
-
-
-
-
Interest and investment income
22.93M
46.65M
10.66M
17.28M
Interest expense
-5.29M
-8.06M
-7.95M
-8.10M
Net interest expenses
17.64M
38.60M
2.71M
9.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
380.74M
225.73M
502.26M
478.57M
Gain or loss from assets sale
1.16M
-9.03M
-
-136.29K
AI content may include mistakes. Learn more
Google apps